Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model

Conclusion: The clinical potential of ERB against DDLPS is herein presented in a PDOX model.

Source: Cancer Genomics and Proteomics - June 22, 2020 Category: Cancer & Oncology Authors: IGARASHI, K., KAWAGUCHI, K., KIYUNA, T., MIYAKE, K., HIGUCHI, T., YAMAMOTO, N., HAYASHI, K., KIMURA, H., MIWA, S., SINGH, S. R., TSUCHIYA, H., HOFFMAN, R. M. Tags: Article Source Type: research